NCT05010902Recruiting
Pregnancy Cohort in Multiple Sclerosis (MS)
Source: ClinicalTrials.gov · Last updated 5 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life. In this prospective observational study, we obtain data on the outcome of pregnancies in MS patients and the influence of pregnancy on clinical, laboratory and MRI parameters in MS.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 21 Jul 2021
- Start date
- 1 Jan 2013
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Charite University, Berlin, Germany
- Diseases
- Multiple sclerosis
- NCT number
- NCT05010902
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Jan 2013 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- alcohol or drug abuse
Other illness
- contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium
Other
- clinically relevant comorbidities
Who the study is looking for
- age \> 18 years
- signed informed consent
- diagnosis of multiple sclerosis or clinically isolated syndrome
Age in the registry: 18 years to 50 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charité Universitätsmedizin Berlin Coordinator of this site? Confirm its status | Berlin | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.